Global News

WIRB-Copernicus Group acquires ThreeWire

Wednesday, May 3, 2017

WIRB-Copernicus Group (WCG), a provider of solutions that measurably improve the quality and efficiency of clinical research, has acquired ThreeWire, a global patient recruitment, enrollment and retention firm that uses a systematic, patient-focused approach to help biopharmaceutical and medical device companies and clinical research organizations achieve their clinical trial enrollment and retention goals.

[Read More]

CureVac appoints Daniel Menichella as CEO of U.S. Subsidiary

Wednesday, May 3, 2017

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, has announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston-based U.S. subsidiary. Menichella, an experienced executive in the biotech industry, will develop CureVac’s U.S. organization with a clear focus on business and corporate development activities around CureVac’s versatile mRNA technology platform.

[Read More]

AstraZeneca, Pieris collaborate for respiratory disease treatments

Wednesday, May 3, 2017

AstraZeneca announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals to develop novel inhaled drugs that leverage Pieris’ Anticalin platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

[Read More]

H3 Biomedicine appoints Lihua Yu chief data sciences officer

Tuesday, May 2, 2017

H3 Biomedicine, a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, announced that Lihua Yu, Ph.D., has been promoted to chief data sciences officer (CDSO). Dr. Yu previously served as H3 Biomedicine’s vice president, Data Science and Information Technology.

[Read More]

BD to acquire Bard for $24B

Monday, May 1, 2017

BD (Becton, Dickinson and Company), a global medical technology company, and C. R. Bard, a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.

[Read More]